Slide 1: Pacific Edge 2020 Financial Results Presentation
PACIFIC EDGE 2020 FINANCIAL RESULTS PRESENTATION
Slide 2: Disclaimer
DISCLAIMER Information The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Pacific Edge Limited. The information in this present
Slide 3: FY20 Commercial Milestones
FY20 COMMERCIAL MILESTONES • COMMERCIAL GROWTH: 14% increase in Operating Revenue and 7% increase in Total Laboratory Throughput; increasing number of customers and urologists adopting and using Cxbladder. • PUBLICATION OF FURTHER PEER-REVIEWED PAPERS: highlighting Cxbladder’s outperformance and add
Slide 4: FY20 Financial Summary
FY20 FINANCIAL SUMMARY $M FY20 FY19 % change Operating Revenue1 4.4 3.8 14% Total Revenue 5.2 5.1 1% Operating Expenses 24.1 23.0 5% Net Loss After Tax (18.9) (17.9) 5% Cash Receipts from Customers 4.4 3.7 19% Net Operating Cashflow (15.4) (17.5) (12%) Cash, cash equivalents and short term deposits
Slide 5: Total Laboratory Throughput
TOTAL LABORATORY THROUGHPUT TOTAL LABORATORY THROUGHPUT (Commercial Tests and User Programmes) • Total Laboratory Throughput increased 7% on pcp to 81% of FY20 Throughput was for 16,861 tests. Commercial Tests • US Total Laboratory Throughput up 6% on pcp to 13,240 +7% tests. Strong 14% year on year
Slide 6: Total Laboratory Throughput by Region and Test Type
TOTAL LABORATORY THROUGHPUT BY REGION AND TEST TYPE Multi-Market and Multi-Product Opportunity for Cxbladder FY20 Regional USA NZ Total Laboratory Throughput Total Laboratory Throughput Laboratory (by region) (by test type) Throughput by Test NZ ROW Triage Cxbladder Detect 69% 21% 17% 5% 20% USA Cxb
Slide 7: Growing Adoption and Commercial Use in New Zealand
GROWING ADOPTION AND COMMERCIAL USE IN NEW ZEALAND • Total Laboratory Throughput for NZ grew by 12% year on NZ Growth year +12% +11% 4000 600 • New Zealand Operating Revenue up 11% year on year. 3500 • Increases driven by increased adoption and commercial 500 use by public healthcare providers in Ne
Slide 8: Commercial Pace Growing in USA
COMMERCIAL PACE GROWING IN USA • Strategy focus is on gaining adoption with large USA Q4 Laboratory Throughput institutions. 3800 • Increase in Total Laboratory Throughput and Operating Revenue driven by increased evaluation, and adoption and commercial use by urologists 3700 +14% growth 3600 • USA
Slide 9: Operating Revenue
OPERATING REVENUE OPERATING REVENUE • Total Operating Revenue from test sales increased 14% on pcp to $4.4m. 5 +14% • The U.S. market accounted for 86% of total Operating Revenue in FY20. 4 • Operating revenue from test sales in the U.S. increased 15% on pcp (+9% in USD terms) to $3.8m* 3 • Operatin
Slide 10: Operating Cashflow
OPERATING CASHFLOW NET OPERATING FY20 FY19 % • Cash receipts from customers increased 19% on pcp CASHFLOWS Change (NZ$M) • Payment terms average 5 months from test to receipt of cash. Receipts from: - Customers 4.4 3.7 19% - Grant providers 1.2 0.8 57% • Payments to suppliers and employees decreased
Slide 11: Operating Expenses
OPERATING EXPENSES OPERATING EXPENSES FY20 FY19 % • Operating Expenses increased 5% on pcp to $24.1m. (NZ$M) Change • In USD terms, U.S. Operating Expenses decreased 2% on pcp. Laboratory Operations 5.2 4.6 13% • U.S. Operating Expenses account for approximately 60% of total Operating Expenses. Rese
Slide 12: Growing Clinical Evidence for Cxbladder
GROWING CLINICAL EVIDENCE FOR CXBLADDER • Publication of peer-reviewed papers is key to gaining inclusion in the LCD and positive reimbursement decisions. • Library of comprehensive clinical evidence for physicians, healthcare payers (reimbursement) and healthcare providers alike. • Application to h
Slide 13: Peer Reviewed Journal Publications Demonstrate Significant Clinical Utility of Cxbladder
PEER REVIEWED JOURNAL PUBLICATIONS DEMONSTRATE SIGNIFICANT CLINICAL UTILITY OF CXBLADDER DIAGNOSTIC OUTPERFORMANCE PUBLISHED IN WORLD #1 CLINICAL JOURNAL • Cxbladder providing enhanced diagnostic outcomes not currently available from existing technology. • Enables physicians to remove the diagnostic
Slide 14: Outlook
PACIFIC EDGE Cancer Diagnostic Company » —s\ OUTLOOK
Slide 15: COVID-19 Response
COVID-19 RESPONSE • Continued to operate as an essential business during COVID-19 restrictions in NZ and the USA. • Cxbladder in-home sampling enabling physicians to maintain timely evaluation and diagnosis of bladder cancer and manage at-risk patients. • Reduction in Total Laboratory Throughput dur
Slide 16: The USA Market Remains Our Focus
THE USA MARKET REMAINS OUR FOCUS A SCALE OPPORTUNITY IN BOTH THE EVALUATION OF HAEMATURIA AND MONITORING FOR RECURRENCE Global Business for Novel Cancer Diagnostics Early detection and better management of cancer 5 January 2019 1. EY-Parthenon business review of the annual addressable market opportu
Slide 17: Institutions in Southeast Asia and the USA Using or Evaluating Cxbladder
INSTITUTIONS IN SOUTHEAST ASIA AND THE USA USING OR EVALUATING CXBLADDER Our in-market strategy is to target large institutional healthcare providers USA USA SOUTH EAST ASIA • Carolina Urologic Research • University of California-San • Singapore General Hospital Center Diego • Tan Tock Seng • City o
Slide 18: Catalysts to Drive Growth Through FY21
CATALYSTS TO DRIVE GROWTH THROUGH FY21 U.S Objectives. • Inclusion in the LCD – expected to have a positive impact on Cxbladder test adoption, revenue growth and operating cash- flow • New commercial agreements completed with transformational institutional healthcare customers • A positive shift in
Slide 19: Enquiries to: David Darling, Chief Executive Officer
Enquiries to: David Darling www.pacificedge.co.nz Chief Executive Officer www.cxbladder.com Pacific Edge Limited www.pacificedgedx.com Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: david.darling@pelnz.com 19
Slide 20: Glossary
GLOSSARY • CMS: Centres for Medicare and Medicaid in the US • Commercial Tests: Tests that have been analysed by Pacific Edge, for a specific customer, including the User Programmes run by customers as part of their adoption process but excluding any tests run for clinical studies. • Laboratory Thro